XAV-939是一种 Tankyrase 抑制剂,可作为细胞疗法中的辅助试剂。XAV939诱导由小鼠胚胎干细胞衍生的中胚层祖细胞的心肌生成,与 SMAD 抑制剂 LDN193189 和 SB431542 联合使用,促进人类多能干细胞系中前脑的诱导。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | PARP ↓ ↑ | PARP1 ↓ ↑ | PARP2 ↓ ↑ | PARP3 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PJ34 HCl |
++
PARP, EC50: 20 nM |
99%+ | |||||||||||||||||
| Rucaparib phosphate |
++++
PARP, Ki: 1.4 nM |
99%+ | |||||||||||||||||
| 3-Aminobenzamide |
++
PARP, IC50: <50 nM |
98% | |||||||||||||||||
| AZD-2461 | ✔ | 99%+ | |||||||||||||||||
| BGP-15 | ✔ | 99%+ | |||||||||||||||||
| NU1025 |
+
PARP, IC50: 400 nM |
98% | |||||||||||||||||
| Benzamide |
+
PARP, IC50: 3.3 μM |
98% | |||||||||||||||||
| Picolinamide |
+
PARP, IC50: 95 μM |
98% | |||||||||||||||||
| AG14361 |
+++
PARP1, Ki: <5 nM |
98+% | |||||||||||||||||
| Iniparib | ✔ | 98% | |||||||||||||||||
| Talazoparib |
++++
PARP1, IC50: 0.57 nM |
99%+ | |||||||||||||||||
| NMS-P118 |
++
PARP1, Kd: 0.009 μM |
97% | |||||||||||||||||
| UPF 1069 |
+
PARP1, IC50: 8.0 μM |
++
PARP2, IC50: 0.3 μM |
98% | ||||||||||||||||
| A-966492 |
++++
PARP1, Ki: 1 nM PARP1, EC50: 1 nM |
+++
PARP2, Ki: 1.5 nM |
99%+ | ||||||||||||||||
| Veliparib |
++
PARP1, Ki: 5.2 nM |
+++
PARP2, Ki: 2.9 nM |
98% | ||||||||||||||||
| Niraparib tosylate |
+++
PARP1, IC50: 3.8 nM |
+++
PARP2, IC50: 2.1 nM |
99%+ | ||||||||||||||||
| Stenoparib |
++++
PARP1, IC50: 1 nM |
++++
PARP2, IC50: 1.2 nM |
98% | ||||||||||||||||
| Olaparib |
+++
PARP1, IC50: 5 nM |
++++
PARP2, IC50: 1 nM |
98% | ||||||||||||||||
| Niraparib |
+++
PARP1, IC50: 3.8 nM |
+++
PARP2, IC50: 2.1 nM |
98% | ||||||||||||||||
| ME0328 |
+
PARP1, IC50: 6.3 μM |
+
PARP3, IC50: 0.89 μM |
99%+ | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | Poly (ADP-ribose) polymerase (PARP) 1 is an essential molecule in DNA damage response by sensing DNA damage and docking DNA repair proteins on the damaged DNA site through a type of posttranslational modification, poly (ADP-Ribosyl)ation (PARylation). PARP inhibitors, which inhibit PARylation through competitively binding to NAD+ binding site of PARP1 and PARP2, have improved clinical benefits for BRCA mutated tumors, leading to their accelerated clinical application[3]. XAV-939 is a potent tankyrase inhibitor that targets Wnt/β-catenin signaling. XAV-939 stabilizes axin by inhibiting tankyrase 1 and tankyrase 2 (IC50s of 5 and 2 nM, respectively), thereby stimulating β-catenin degradation. XAV939 binds tightly to the catalytic (PARP) domains of TNKS1 and TNKS2 (Kds of 99 and 93 nM, respectively)[4].XAV939 (0.5 μM, 1.0 μM) reduces DNA-PKcs protein levels 50% of the relative DMSO control in human lymphoblasts[5]. XAV939 induces a second wave of pro-cardiomyocyte gene expression as shown by increased Mesp1 and Isl1expression 2 to 4 days after Wnt inhibition, and by increased Nkx2.5 expression 4 to 6 days after XAV939 addition[6]. XAV-939 (10 nM) has a suppressive effect on elevated MMP-13 levels in both IL-1β-induced SW 1353 cells. XAV-939 (3 mL, 10 nM) has a suppressive effect on elevated MMP-13 levels in the rat OA model[7].XAV-939(1mg/mL,i.p.) ameliorates the psoriasiform skin disease induced by IMQ. XAV-939 results in a significant decrease in the IMQ-induced epidermal hyperplasia (indicated by acanthosis) and dermal inflammatory infiltrates in mice[8]. |
| Concentration | Treated Time | Description | References | |
| human pluripotent stem cell-derived GnRH neurons | 10 µM | 10 days | To investigate the effect of Wnt signaling inhibition on GnRH neuron differentiation, it was found that Wnt inhibition significantly improved the differentiation efficiency of GnRH neurons | Stem Cells. 2022 Dec 31;40(12):1107-1121. |
| pancreatic progenitor cells | 5 µM | 4 days | To inhibit the WNT signaling pathway and study its effect on the differentiation of FOXA2-deficient pancreatic progenitor cells. The results showed that WNT inhibition partially reversed the phenotype associated with FOXA2 deficiency. | Cell Death Dis. 2021 Jan 20;12(1):103. |
| Mouse epiblast stem cells (EpiSCs) | 10 µM | XAV-939 promotes the stable maintenance of EpiSCs by inhibiting the Wnt signaling pathway and reducing spontaneous differentiation. | Stem Cell Reports. 2015 Apr 14;4(4):744-57. | |
| MDA-MB-231 | 5 μM | 48 h | Inhibition of cell proliferation | J Transl Med. 2013 Nov 4;11:280. |
| HCC-1937 | 5 μM | 48 h | Inhibition of cell proliferation | J Transl Med. 2013 Nov 4;11:280. |
| HCC-1143 | 5 μM | 48 h | Inhibition of cell proliferation | J Transl Med. 2013 Nov 4;11:280. |
| BT-549 | 5 μM | 48 h | Inhibition of cell proliferation | J Transl Med. 2013 Nov 4;11:280. |
| OPCs | 0.5 μM | 3 days | XAV-939 significantly rescued Mbp expression and OL morphology in the Eed null OL lineage | Cell Rep. 2020 Sep 15;32(11):108147. |
| mouse oligodendrocyte progenitor cells | 0.01 or 0.1μM | 24 h | increased levels of both Axin2 and Axin1 proteins, promoted oligodendrocyte differentiation | Nat Neurosci. 2011 Jun 26;14(8):1009-16. |
| fibroblasts | 10 µM | DPC-Exos attenuated the inhibitory effect of XAV939, leading to an increase in the expression levels of these molecules. | J Nanobiotechnology. 2024 Jul 19;22(1):425. | |
| fibroblasts | 10 µM | XAV939 significantly inhibited the proliferation and migration of fibroblasts, suggesting that blocking the Wnt/β-catenin signaling pathway could hinder the activity of fibroblasts. | J Nanobiotechnology. 2024 Jul 19;22(1):425. | |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Mkx+/- mouse Achilles tendon injury model | Local injection | 4 µM | Single administration, observed for 28 or 52 days | XAV-939 improved tendon regeneration in mice by inhibiting the Wnt/β-Catenin signaling pathway, reducing fibrosis and angiogenesis, and enhancing biomechanical properties. | Sci Rep. 2022 Nov 21;12(1):20003 |
| Mouse | Spinal cord demyelination model | Spinal cord injection | 0.1μM | Single injection, duration of 6 days | Accelerated oligodendrocyte progenitor cell differentiation and myelin regeneration | Nat Neurosci. 2011 Jun 26;14(8):1009-16. |
| Mice | Full-thickness skin excision model | Intraperitoneal injection | 1.25 mg/kg | Four injections on day 1 | After treatment with XAV939, wound closure was significantly slower compared to other groups, suggesting that blocking the Wnt/β-catenin signaling pathway could impede wound healing. Specifically, the wound closure rate and the number of new HFs in DPC-Exos + X group was significantly reduced compared to the DPC-Exos group, which suggested that blocking the Wnt/β-catenin signaling pathway could inhibit the promoting effects of DPC-Exos on wound healing and HF regeneration. | J Nanobiotechnology. 2024 Jul 19;22(1):425. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
3.20mL 0.64mL 0.32mL |
16.01mL 3.20mL 1.60mL |
32.02mL 6.40mL 3.20mL |
|
| CAS号 | 284028-89-3 |
| 分子式 | C14H11F3N2OS |
| 分子量 | 312.31 |
| SMILES Code | O=C1C(CSCC2)=C2N=C(C3=CC=C(C(F)(F)F)C=C3)N1 |
| MDL No. | MFCD16879017 |
| 别名 | NVP-XAV939 |
| 运输 | 蓝冰 |
| InChI Key | KLGQSVMIPOVQAX-UHFFFAOYSA-N |
| Pubchem ID | 135418940 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, store in freezer, under -20°C |
| 溶解方案 |
DMSO: 15 mg/mL(48.03 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1